(RX) shareholders by agreeing to sell IMS Health at an unfair price thereby harming IMS Health, Inc and its shareholders”, “whether the directors of IMS Health, Inc may have breached their fiduciary duties by not acting in RX shareholders' best interests”, and "the Company may not have adequately shopped itself around before entering into this transaction and, pursuant to this transaction, TPG Capital and the CPP Investment Board may be underpaying for IMS Health, thus unlawfully harming IMS (RX)shareholders." IMS Health Incorporated, located in Norwalk, CT, reported in 2007 Total Revenue of $2.19257billion with a Net Income of $234.04million and in 2008 Total Revenue of $2.32953billion with a Net Income of $311.25million, and is a provider of market intelligence to the pharmaceutical and healthcare industries. Full Article at PR-Inside.com